G1T38, a novel, oral, potent and selective CDK4/6 inhibitor for the treatment of Rb competent tumors

被引：0
|
作者：
Sorrentino, Jessica A.
Bisi, John E.
Roberts, Patrick J.
Strum, Jay C.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2824
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2824
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A novel CDK4/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma
    Zuo, Pengcheng
    Li, Yaopeng
    Wang, Tantan
    Lin, Xingyu
    Wu, Zhen
    Zhang, Junting
    Liao, Xuebin
    Zhang, Liwei
    JOURNAL OF NEURO-ONCOLOGY, 2023, 163 (01) : 159 - 171
  • [42] A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
    Yap, T. A.
    Moore, K. N.
    Patel, M.
    Henick, B. S.
    Do, D.
    Iheanacho, A.
    Zhang, H.
    Roche, M.
    Newberry, K.
    Hsieh, A.
    Juric, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S765 - S765
  • [43] ETH-155008, a Novel Selective Dual Inhibitor of FLT3 and CDK4/6 in Preclinical Treatment of Acute Myeloid Leukemia
    Liu, Changnian
    Liu, Bin
    Xu, Chunping
    Zhang, Pan
    Li, Bin
    Ji, Bin
    Zhang, Bin
    Liu, Qingjun
    Zhang, James
    Yu, Chengzhi
    BLOOD, 2019, 134
  • [44] A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans
    Zhang, Hua
    Yan, Shu
    Zhan, Yan
    Ma, Sheng
    Bian, Yicong
    Li, Shaorong
    Tian, Junjun
    Li, Guangze
    Zhong, Dafang
    Diao, Xingxing
    Miao, Liyan
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [45] CDKI-15, a novel and highly selective CDK4/6 inhibitor: discovery, in vitro and in vivo anticancer efficacy
    Tadesse, Solomon
    Bantie, Laychiluh
    Tomusange, Khamis
    Islam, Saiful
    Rahaman, Muhammed H.
    Noll, Benjamin
    Lam, Frankie
    Yu, Mingfeng
    Wang, Shudong
    CANCER RESEARCH, 2017, 77
  • [46] CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
    Jiayuan Wang
    Qingqing Li
    Jiajia Yuan
    Jingyuan Wang
    Zuhua Chen
    Zhentao Liu
    Zhongwu Li
    Yumei Lai
    Jing Gao
    Lin Shen
    Journal of Translational Medicine, 15
  • [47] An Intact G1/S checkpoint determines response to CDK4/6 inhibitor in breast cancer
    Vijayaraghavan, Smruthi
    Keyomarsi, Khandan
    CANCER RESEARCH, 2016, 76
  • [48] CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
    Wang, Jiayuan
    Li, Qingqing
    Yuan, Jiajia
    Wang, Jingyuan
    Chen, Zuhua
    Liu, Zhentao
    Li, Zhongwu
    Lai, Yumei
    Gao, Jing
    Shen, Lin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2017, 15
  • [49] Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells
    Yan-Fang Tao
    Na-Na Wang
    Li-Xiao Xu
    Zhi-Heng Li
    Xiao-Lu Li
    Yun-Yun Xu
    Fang Fang
    Mei Li
    Guang-Hui Qian
    Yan-Hong Li
    Yi-Ping Li
    Yi Wu
    Jun-Li Ren
    Wei-Wei Du
    Jun Lu
    Xing Feng
    Jian Wang
    Wei-Qi He
    Shao-Yan Hu
    Jian Pan
    Cancer Cell International, 17
  • [50] Molecular mechanism of G1 arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells
    Tao, Yan-Fang
    Wang, Na-Na
    Xu, Li-Xiao
    Li, Zhi-Heng
    Li, Xiao-Lu
    Xu, Yun-Yun
    Fang, Fang
    Li, Mei
    Qian, Guang-Hui
    Li, Yan-Hong
    Li, Yi-Ping
    Wu, Yi
    Ren, Jun-Li
    Du, Wei-Wei
    Lu, Jun
    Feng, Xing
    Wang, Jian
    He, Wei-Qi
    Hu, Shao-Yan
    Pan, Jian
    CANCER CELL INTERNATIONAL, 2017, 17
12345